imatinib mesylate has been researched along with Ache in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelfattah, R; Hamza, MS; Moussa, HS; Omran, MM; Shouman, SA | 1 |
| Bettiol, A; Chinellato, A; Crescioli, G; Gherlinzoni, F; Giusti, P; Lombardi, N; Marconi, E; Vannacci, A; Walley, T | 1 |
| Erben, P; Fabarius, A; Griesshammer, M; Hehlmann, R; Hochhaus, A; Hofmann, WK; Lengfelder, E; Merx, K; Reiter, A | 1 |
| Chen, MF; Chiang, KC; Fu, CJ; Jan, YY; Yeh, CN; Yen, TC | 1 |
| Ammerlaan, RA; Chu, IW; Cornelissen, JJ; Deenik, W; Falkenburg, JH; Janssen, JJ; Kersten, MJ; Ossenkoppele, GJ; Schattenberg, A; Schipperus, M; Sinnige, HA; Smit, WM; Sonneveld, P; Thielen, N; Valk, PJ; van der Holt, B; van Marwijk Kooy, R; Verhoef, GE | 1 |
| Ericson, ME; Gupta, K; Gupta, M; Luk, K; Nguyen, J; Simone, DA; Vang, D; Vincent, L | 1 |
| Close, J; Lottenberg, R; Murphy, M; Rajasekhar, A | 1 |
| Ceko, M; le Coutre, P; Lewin, GR; Milenkovic, N; Westermann, J | 1 |
| Brümmendorf, TH; Cortes, JE; Dmoszynska, A; Duvillié, L; Gambacorti-Passerini, C; Gogat Marchant, K; Kantarjian, HM; Khattry, N; Lipton, JH; Pavlov, D; Rossiev, V; Wong, RS | 1 |
| Novelli, EM; Redner, RL | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Bloomfield, K; Braunschweig, I; Chadburn, A; Darji, J; Gotlib, V; Patel, A | 1 |
| Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM | 1 |
| Cacchione, R; Gadano, AC; Mandó, OG; Marciano, S; Ridruejo, E; Villamil, AG | 1 |
1 review(s) available for imatinib mesylate and Ache
| Article | Year |
|---|---|
Eosinophilic variant of chronic myeloid leukemia with vascular complications.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Benzamides; Bone Marrow; Diagnostic Errors; Eosinophilia; Fingers; Gangrene; Humans; Imatinib Mesylate; Leg; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pain; Piperazines; Pyrimidines; Radiography; Vasculitis; Vitamins | 2003 |
5 trial(s) available for imatinib mesylate and Ache
| Article | Year |
|---|---|
Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Exanthema; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pain; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Time Factors; Young Adult | 2018 |
Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.
Topics: Aged; Aged, 80 and over; Benzamides; Bone Marrow; Combined Modality Therapy; Female; Gastrointestinal Diseases; Humans; Imatinib Mesylate; Janus Kinase 2; Leukocyte Count; Male; Middle Aged; Mutation, Missense; Organ Size; Pain; Phlebotomy; Piperazines; Point Mutation; Polycythemia Vera; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Spleen; Treatment Outcome | 2013 |
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Treatment Outcome; Young Adult | 2013 |
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Alanine Transaminase; Aniline Compounds; Antineoplastic Agents; Aspartate Aminotransferases; Benzamides; Diarrhea; Female; Fever; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Myalgia; Nitriles; Pain; Piperazines; Pyrimidines; Quinolines; Vomiting | 2014 |
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid | 2004 |
8 other study(ies) available for imatinib mesylate and Ache
| Article | Year |
|---|---|
Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pain; Quality of Life | 2022 |
Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Liver Neoplasms; Middle Aged; Osteonecrosis; Pain; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Range of Motion, Articular; Tibia | 2013 |
Mast cell activation contributes to sickle cell pathobiology and pain in mice.
Topics: Anemia, Sickle Cell; Animals; Benzamides; Cells, Cultured; Cytokines; Ganglia, Spinal; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hyperalgesia; Hypoxia; Imatinib Mesylate; Leukocyte Count; Mast Cells; Mice; Mice, Knockout; Mice, Transgenic; Microscopy, Confocal; Neurogenic Inflammation; Nociceptors; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin; Substance P | 2013 |
Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2014 |
Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Case-Control Studies; Cold Temperature; Female; Hot Temperature; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nociception; Pain; Pain Perception; Pain Threshold; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Skin | 2014 |
Knee pain: ACL, MCL, or CML?
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Knee Joint; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Pain; Piperazines; Pyrimidines | 2010 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Imatinib-induced fatal acute liver failure.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antineoplastic Agents; Benzamides; Fatal Outcome; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Middle Aged; Pain; Piperazines; Pyrimidines | 2007 |